MedTrace Logo

ALPHA LONG Study- BioMatrix AlphaTM Stent Study in Patients With CAD

NCT05799963 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2024-11-05

No results posted yet for this study

Summary

Prospective, multi-center, open-label single-arm study designed to enroll 85 patients in up to 15 centers in up to 3 European countries.

All patients will be followed up for 9 months. The "BMX Alpha Registry" study will serve as reference and historic comparator.

Conditions

Interventions

DEVICE

BioMatrix Alpha

Patient will be treated with BioMatrix Alpha

Sponsors & Collaborators

  • Biosensors Europe SA

    lead INDUSTRY

Principal Investigators

  • Scot Garg, Professor · Royal Blackburn Hospital, Haslingden Rd, Blackburn BB2 3HH, UK

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-09
Primary Completion
2025-07-31
Completion
2026-03-31

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05799963 on ClinicalTrials.gov